title: A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
abstract: The duration of the antiemetic effect of granisetron was examined in a pilot study of patients (n = 26) undergoing a standard emetogenic stimulus in the form of total body irradiation fractionated over 3-4 days, in a randomized comparison with twice-daily ondansetron. A single intravenous dose of granisetron at the onset of therapy was effective over the entire follow-up period in 50% (6/12) of patients, compared with 77% (10/13) prescribed twice-daily oral ondansetron for 3 or 4 days. The response rate within the first 24 hours from the start of irradiation was 67% (8/12) for granisetron and 77% (10/13) for ondansetron. Granisetron and ondansetron were therefore of similar efficacy within the first 24-hour period, but granisetron was less efficaceous more than 24 hours after the onset of therapy. Patients who required a second dose of granisetron did so at intervals of 12, 42, 47 and 48 hours following the first fraction of radiotherapy. The cost per patient in this study was pound 48 for granisetron and pound 54 for ondansetron, but the dose scheduling we used cannot be recommended in view of the lower effectiveness of granisetron.
authors.affiliation: Meyerstein Institute of Clinical Oncology, Middlesex Hospital, London, UK.
authors.forename: S J
authors.initials: SJ
authors.lastname: Gibbs
authors.forename: A M
authors.initials: AM
authors.lastname: Cassoni
mesh_terms: D000284:Administration, Oral; D000932:Antiemetics / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D017829:Granisetron / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D010865:Pilot Projects; D011879:Radiotherapy Dosage; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects; D014839:Vomiting / Q000517:prevention & control; D014916:Whole-Body Irradiation / Q000009:adverse effects*
chemical_list: D000932:Antiemetics; D017829:Granisetron; D017294:Ondansetron